Home / News / India News / Article /
Glenmark announces 400 mg 'FabiFlu' for COVID-19 treatment
Updated On: 06 August, 2020 03:52 PM IST | Mumbai | IANS
Mid Day Short Description
Listen to this article :

This picture has been used for representation purpose
Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral - FabiFlu -- for the treatment of mild to moderate Covid-19 in India.
It was the first Indian company to commercially launch an antiviral drug - Favipiravir with brand name FabiFlu - for the treatment of Covid-19 patients. The company received marketing and manufacturing approval from the Drug Controller General of India and launched the product in the Indian market on June 20.


